20-F: Haleon Delivers Strong 2024 Performance, Boosts Shareholder Returns

Haleon reports solid 2024 results with organic revenue growth and increased shareholder returns through buybacks and dividends.

Summary

• Haleon's 2024 results show a positive trajectory with a focus on becoming a more agile and competitive organization.
• The company achieved organic revenue growth of 5.0% and organic operating profit growth of 9.8%.
• Adjusted operating margin increased by 100bps on an organic basis.
• Over 1 billion was returned to shareholders through share buybacks and dividend payments.
• The company increased its stake in the TSKF joint venture in China to 88%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial performance and strategic progress, indicating a favorable sentiment.

Positives

• Strong financial performance with organic revenue and operating profit growth.
• Disciplined capital allocation with strategic divestments and reinvestments.
• Significant shareholder returns through buybacks and increased dividends.
• Progress in health inclusivity goals, empowering over 50 million people.
• Advancements in sustainability initiatives, including reducing carbon emissions and using bioplastic packaging.

Negatives

• Reported revenue declined by 0.6% due to foreign exchange headwinds and net M&A impact.
• Adjusted operating margin decreased by 30bps on a reported basis.
• Pain Relief category saw only 0.1% organic growth.
• Respiratory Health category declined 3.4% due to a softer cold and flu season.

Risks

• Competition from other consumer healthcare companies.
• Potential disruptions in the global supply chain.
• Dependence on key retail customers.
• Failure to comply with regulations regarding the use of personal data.
• Geopolitical instability and macroeconomic uncertainty.

Future Outlook

Haleon expects to deliver organic revenue growth of 4-6% in 2025, with organic operating profit growth ahead of that.

Management Comments

• Brian McNamara stated that 2024 was a year of good progress for Haleon, with the business continuing to gather operational momentum.
• Dawn Allen expressed excitement about joining Haleon and confidence in its strategy.

Industry Context

The document notes the broader industry trend of pharmaceutical companies demerging their consumer healthcare divisions, highlighting Kenvue's formation and Sanofi's plans for Opella, indicating a continued focus on specialized consumer health businesses.

Comparison to Industry Standards

• The report mentions key competitors like Bayer, Church & Dwight, Colgate-Palmolive, Nestle, Perrigo, Proctor & Gamble, Reckitt, and Unilever, positioning Haleon within a competitive landscape.
• Haleon's market share in various categories is compared to the top players, highlighting its leadership in Therapeutic Oral Health (c.45% market share) and its position as the largest player in the VMS category (approximately 3% global market share).

Management Changes

Legal Proceedings

• GSK and/or Pfizer have been named as defendants in personal injury lawsuits, as well as economic injury and medical monitoring class actions, filed in the US involving Zantac.
• The Group is party to civil proceedings in Germany brought by or on behalf of retailers against the Group and other manufacturers of branded drugstore products, alleging that the exchange of information within the working group led to higher purchase prices being paid by the retailers.

Related Party Transactions

• The Group purchased 102,272,727 ordinary shares from Pfizer on 21 March 2024 for 315 million.
• The Group purchased 60,526,315 ordinary shares from Pfizer on 3 October 2024 for 230 million.

Stakeholder Impact

• Consumers benefit from innovative products and health inclusivity initiatives.
• Customers receive safe, innovative, and accessible products.
• Employees are part of a purpose-led, inclusive company.
• Governments benefit from effective, safe, and accessible products.
• Health Professionals receive effective and safe products supported by reliable scientific information.
• Investors receive sustainable performance and long-term shareholder value.
• Suppliers value trust-based relationships and responsible practices.

Next Steps

• Continued transformation of Haleon into an agile, consumer-focused business.
• Further evolving strategy and culture to capitalize on significant opportunities.
• Generating value through disciplined capital allocation that maximizes shareholder returns.
• Maintaining strong corporate governance and ethical behaviors.

Key Dates

Keywords

Haleon, financial results, organic growth, shareholder returns, consumer healthcare, sustainability, capital allocation, revenue, operating profit, dividends, share buyback